Thus, in this study, we observed the percentage of LCSCs, the number of tubules produced by human umbilical vein endothelial cells (HUVECs), and the expression changes in the angiogenesis-related molecules VEGFA, delta-like ligand 4 (Dll4), and Notch1 in iRFA cancer cells and mouse models treated with amarogentin in both the presence and absence of p53 to reveal the antiangiogenesis effects and mechanisms of amarogentin in liver cancer after iRFA treatment. The gene discussed is TP53; the disease is liver cancer.